{"organizations": [], "uuid": "21a9c8b97fb7c063dae2095e5111e28118083aba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/Reuters/UKBusinessNews?format=xml", "section_title": "Reuters: Business News", "url": "https://uk.reuters.com/article/us-fresenius-care-outlook/fresenius-medical-cuts-2018-sales-target-after-drug-dosage-shift-idUKKBN1HT0Q1", "country": "US", "domain_rank": 408, "title": "Fresenius Medical cuts 2018 sales target after drug dosage shift", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-22T18:13:00.000+03:00", "replies_count": 0, "uuid": "21a9c8b97fb7c063dae2095e5111e28118083aba"}, "author": "", "url": "https://uk.reuters.com/article/us-fresenius-care-outlook/fresenius-medical-cuts-2018-sales-target-after-drug-dosage-shift-idUKKBN1HT0Q1", "ord_in_thread": 0, "title": "Fresenius Medical cuts 2018 sales target after drug dosage shift", "locations": [], "entities": {"persons": [{"name": "victoria bryan", "sentiment": "none"}, {"name": "david evans", "sentiment": "none"}], "locations": [{"name": "berlin", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "fresenius medical", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "fresenius medical care", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 22, 2018 / 3:16 PM / Updated 31 minutes ago Fresenius Medical cuts 2018 sales target after drug dosage shift Reuters Staff 1 Min Read \nBERLIN (Reuters) - German dialysis specialist Fresenius Medical Care ( FMEG.DE ) cut its 2018 sales target after a reduction in the dosing of calcimimetic drugs in the United States. \nThe company said on Sunday it now expects sales to rise by 5-7 percent at constant currency, compared with a previous forecast for a rise of around 8 percent. \nIt confirmed a target for net income to rise by 13-15 percent at constant currency. Reporting by Victoria Bryan, editing by David Evans", "external_links": [], "published": "2018-04-22T18:13:00.000+03:00", "crawled": "2018-04-22T18:58:31.010+03:00", "highlightTitle": ""}